The overarching goal of the Tissue and Pathology Core (TPC) is to facilitate translational research involving the acquisition or use of biological samples within the SPORE. To accomplish this goal, the Core will offer a range of services for SPORE investigators. These include: 1) Providing a tissue and blood repository;2) Collecting, storing, processing, and analyzing tissue and blood from participants on SPORE clinical trials;and 3) Providing a variety of readily accessible pathology and technical services, integrated with clinical information. In addition to standard pathology techniques, the TPC will offer several state-of-the- art technologies including circulating tumor cell capture and analysis. Lastly, the TPC will centralize and prioritize access of biological samples to investigators collected in the SPORE. A key strength of the TPC is the ability to bank frozen tumor tissue. The Core has a pre-existing collection of over 2,600 frozen breast cancer specimens acquired during the previous SPORE and this resource will continue to be expanded. The Core also will maintain a blood sample repository that will build upon the current collection of samples from 10,000 patients with breast cancer and from 2,400 individuals at high risk of developing breast cancer. In order to optimize the utility of the specimen collections for translational research, the samples in the repository are linked to clinical data through caTissue. The TPC will work closely with the Clinical Trials Core to procure research biopsies and other tissues from participants on SPORE clinical trials. The TPC will use caTissue to catalogue these specimens as well. Importantly, the Core will be directly involved in the analysis of these specimens, and will interact extensively with the four projects. To ensure that project-related tissue based research is seamless;a specific team pathologist from the TPC has been identified as a collaborator for each project. In addition to working with SPORE investigators, the Core will work with investigators throughout the DF/HCC, with other Breast Cancer SPORE programs, and with researchers at centers around the world. The TPC facilitates clinical research involving the acquisition or use of biological samples within the SPORE. Three of the four projects have proposed clinical trials that include research biopsies (Projects 2, 3, 4). The TPC will oversee the collection, storage, quality assessment, and processing of these biopsies. During the course of the SPORE, we anticipate supporting other investigators who will conduct tissue-intensive trials either as part of the projects or through a career development program award or developmental project.

Public Health Relevance

The Tissue and Pathology Core facilitates translational research involving the acquisition or use of biological samples. The collection of tissue and blood from healthy and diseased women is vital to translational research. Having the TPC resource will advance our ability to prevent, diagnose and treat breast cancer. The Core will enable the SPORE toward translational discoveries in the near-term, and a new wave of scientific challenges.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA168504-01A1
Application #
8607760
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (O1))
Project Start
2013-09-17
Project End
2018-07-31
Budget Start
2013-09-17
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$184,409
Indirect Cost
$26,276
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Spangle, Jennifer M; Dreijerink, Koen M; Groner, Anna C et al. (2016) PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Rep 15:2692-704
Montaser-Kouhsari, Laleh; Knoblauch, Nicholas W; Oh, Eun-Yeong et al. (2016) Image-guided Coring for Large-scale Studies in Molecular Pathology. Appl Immunohistochem Mol Morphol 24:431-5
Morganella, Sandro; Alexandrov, Ludmil B; Glodzik, Dominik et al. (2016) The topography of mutational processes in breast cancer genomes. Nat Commun 7:11383
Cheng, H; Liu, P; Ohlson, C et al. (2016) PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene 35:2961-70
Choi, Young Eun; Meghani, Khyati; Brault, Marie-Eve et al. (2016) Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep 14:429-39
Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6
Wang, Q; Liu, P; Spangle, J M et al. (2016) PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 35:3607-12
Nik-Zainal, Serena; Davies, Helen; Staaf, Johan et al. (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534:47-54
Smid, Marcel; Rodríguez-González, F Germán; Sieuwerts, Anieta M et al. (2016) Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun 7:12910
Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381

Showing the most recent 10 out of 38 publications